RPL17 and central nervous system cancer: Patients with hypermutated gliomas treated with PD-1 blockade had similar PFS and OS vs. those with non-hypermutated gliomas (1.38 vs. 1.87 mo, 8.7 vs. 9.96 mo). Patients with hypermutated gliomas had shorter mOS with PD-1 blockade vs. other treatments (8.07 vs. 16.10 mo, p = 0.02)